Pomegranate (Seed) Extract (40% Polyphenols)

Food Code: 253532

Standardized pomegranate seed extract delivering 40% polyphenols (ellagitannins incl. punicalagins) for nutraceutical formulations; human evidence supports modest blood-pressure benefits.

฿35.00
gram
Min: 0g
pieces
trending_down

Unit price will be cheaper for larger size

The price will be calculated based on the size you enter

Pomegranate (Seed) Extract (40% Polyphenols) Standardized to 40% polyphenols (ellagitannins incl. punicalagins) is a nutraceutical botanical extract used to deliver pomegranate polyphenols in capsules, tablets, and functional foods.


Benefit Typical study dose* Key human findings High-quality sources
1 Blood pressure support (modest) Commonly 1 capsule/day; 4–12 weeks (varies by extract and study design) Across randomized trials, pomegranate products (juice/extract) are associated with modest average reductions in systolic and diastolic blood pressure, with substantial between-study variability. In one double-blind RCT of pomegranate extract capsules (8 weeks), diastolic BP decreased significantly vs placebo. PubMed (2024 meta-analysis)
Cambridge (double-blind RCT)
2 Cardiometabolic markers (mixed) Varies widely (juice/extract); typically weeks to months Clinical studies report improvements in some endpoints (e.g., triglycerides, LDL/total cholesterol, glycemia/insulin resistance) in some settings, but findings are inconsistent and likely sensitive to dose, extract profile, and baseline risk. MDPI (systematic review)
3 Skin appearance (early evidence) Standardized extract daily for 4 weeks (75 mg punicalagin per capsule) A small randomized, double-blind, placebo-controlled study reported improvements in image-based facial wrinkle severity after 4 weeks of standardized pomegranate extract supplementation. MDPI (RCT)
4 Gut microbiome / urolithins (biomarker-driven) Varies by extract; response depends on microbiome “metabotype” Ellagitannins/ellagic acid can be converted by gut microbes into urolithins (e.g., urolithin A), but individuals differ markedly. A human study in overweight/obese adults reported microbiome and gut-metabolite shifts linked to urolithin A production. RSC Food & Function

*Dose varies by extract profile and standardization. This product is standardized to 40% polyphenols; for example, 250 mg/day extract delivers ~100 mg/day polyphenols (40%).



Mechanistic highlights

  1. Ellagitannins / punicalagins as key actives: Pomegranate polyphenols are dominated by ellagitannins (incl. punicalagins) and related compounds that contribute to antioxidant and vascular signaling effects.
  2. Microbiome conversion to urolithins: Ellagitannins/ellagic acid can be converted to urolithins; the magnitude of this conversion depends on the individual microbiome, influencing downstream biomarker responses.
  3. Vascular pathways (still being studied): Human and mechanistic literature commonly discusses endothelial function, oxidative stress, and ACE-related signaling as potential contributors to blood-pressure effects.
  4. Seed-vs-peel note (specification matters): Pomegranate peel is often richer in polyphenols, while seeds are frequently associated with seed oil (punicic acid, not a polyphenol). For “seed” materials, standardization (like 40% polyphenols) is critical to ensure a polyphenol-driven profile.


Safety & practical use

  • Usual supplemental range: Commonly 50–500 mg/day extract; adjust to target delivered polyphenols (e.g., 40% standardized extract).
  • Drug interactions: Case reports suggest a possible interaction with warfarin; reviews discuss potential CYP3A4/CYP2C9 interactions, with limited and mixed clinical evidence.
  • Blood pressure medications: If taking antihypertensives, consider medical oversight due to the possibility of additive blood-pressure lowering in some individuals.
  • Allergy risk: Rare allergic reactions have been reported.
  • Pregnancy/breastfeeding: Safety data for concentrated extracts is limited; use medical guidance.
  • References: PubMed (warfarin case report); MDPI (CYP review); CAM Cancer

  • Room (25-40C)
  • 24 Months from manufacturing or testing date.
  • 50mg - 500mg
  • 50mg - 500mg
  • Add into water phase. Avoid temperature above 60C.
  • Avoid heat above 40C
  • 0.00 - 0.00
  • -
Test Name Specification
Appearance Brown powder
Assay (Total polyphenols) 40% Min
Odor Characteristics
Heavy Metals 10ppm Max
As 1ppm Max
Pb 1ppm Max
Cd 0.3ppm Max
Hg 0.1ppm Max
Aflatoxins 10ppm Max
Total Plate Count 1000CFU/g Max
E.Coli Negative in 10g
Salmonella Negative in 10g
Staphylococcus aureus Negative in 10g
Coliform 10CFU/g Max
Yeast and mold 100CFU/g Max

Pomegranate (Seed) Extract (40% Polyphenols)

Standardized pomegranate seed extract delivering 40% polyphenols (ellagitannins incl. punicalagins) for nutraceutical formulations; human evidence supports modest blood-pressure benefits.

Pomegranate (Seed) Extract (40% Polyphenols) Standardized to 40% polyphenols (ellagitannins incl. punicalagins) is a nutraceutical botanical extract used to deliver pomegranate polyphenols in capsules, tablets, and functional foods.


Benefit Typical study dose* Key human findings High-quality sources
1 Blood pressure support (modest) Commonly 1 capsule/day; 4–12 weeks (varies by extract and study design) Across randomized trials, pomegranate products (juice/extract) are associated with modest average reductions in systolic and diastolic blood pressure, with substantial between-study variability. In one double-blind RCT of pomegranate extract capsules (8 weeks), diastolic BP decreased significantly vs placebo. PubMed (2024 meta-analysis)
Cambridge (double-blind RCT)
2 Cardiometabolic markers (mixed) Varies widely (juice/extract); typically weeks to months Clinical studies report improvements in some endpoints (e.g., triglycerides, LDL/total cholesterol, glycemia/insulin resistance) in some settings, but findings are inconsistent and likely sensitive to dose, extract profile, and baseline risk. MDPI (systematic review)
3 Skin appearance (early evidence) Standardized extract daily for 4 weeks (75 mg punicalagin per capsule) A small randomized, double-blind, placebo-controlled study reported improvements in image-based facial wrinkle severity after 4 weeks of standardized pomegranate extract supplementation. MDPI (RCT)
4 Gut microbiome / urolithins (biomarker-driven) Varies by extract; response depends on microbiome “metabotype” Ellagitannins/ellagic acid can be converted by gut microbes into urolithins (e.g., urolithin A), but individuals differ markedly. A human study in overweight/obese adults reported microbiome and gut-metabolite shifts linked to urolithin A production. RSC Food & Function

*Dose varies by extract profile and standardization. This product is standardized to 40% polyphenols; for example, 250 mg/day extract delivers ~100 mg/day polyphenols (40%).



Mechanistic highlights

  1. Ellagitannins / punicalagins as key actives: Pomegranate polyphenols are dominated by ellagitannins (incl. punicalagins) and related compounds that contribute to antioxidant and vascular signaling effects.
  2. Microbiome conversion to urolithins: Ellagitannins/ellagic acid can be converted to urolithins; the magnitude of this conversion depends on the individual microbiome, influencing downstream biomarker responses.
  3. Vascular pathways (still being studied): Human and mechanistic literature commonly discusses endothelial function, oxidative stress, and ACE-related signaling as potential contributors to blood-pressure effects.
  4. Seed-vs-peel note (specification matters): Pomegranate peel is often richer in polyphenols, while seeds are frequently associated with seed oil (punicic acid, not a polyphenol). For “seed” materials, standardization (like 40% polyphenols) is critical to ensure a polyphenol-driven profile.


Safety & practical use

Mechanism -
Appearance -
Longevity -
Strength -
Storage -
Shelf Life -
Allergen(s) -
Dosage (Range) -
Dosage (Per Day) -
Mix Method -
Heat Resistance -
Stable in pH range -
Solubility -
Product Types -
INCI -

Purchase History for

Loading purchase history...